While existing studies on SGLT2 inhibitors have primarily focused on chronic diseases such as heart failure, with numerous trials demonstrating their benefits in reducing mortality and improving cardiac outcomes [8,35,36,37], the potential of these drugs in acute settings, particularly in early-phase interventions, remains largely unexplored. This evidence concerns the gene SLC5A2 and heart failure.